壹生大学

壹生身份认证协议书

本项目是由壹生提供的专业性学术分享,仅面向医疗卫生专业人士。我们将收集您是否是医疗卫生专业人士的信息,仅用于资格认证,不会用于其他用途。壹生作为平台及平台数据的运营者和负责方,负责平台和本专区及用户相关信息搜集和使用的合规和保护。
本协议书仅为了向您说明个人相关信息处理目的,向您单独征求的同意,您已签署的壹生平台《壹生用户服务协议》和《壹生隐私政策》,详见链接:
壹生用户服务协议:
https://apps.medtrib.cn/html/serviceAgreement.html
壹生隐私政策:
https://apps.medtrib.cn/html/p.html
如果您是医疗卫生专业人士,且点击了“同意”,表明您作为壹生的注册用户已授权壹生平台收集您是否是医疗卫生专业人士的信息,可以使用本项服务。
如果您不是医疗卫生专业人士或不同意本说明,请勿点击“同意”,因为本项服务仅面向医疗卫生人士,以及专业性、合规性要求等因素,您将无法使用本项服务。

同意

拒绝

同意

拒绝

知情同意书

同意

不同意并跳过

工作人员正在审核中,
请您耐心等待
审核未通过
重新提交
完善信息
{{ item.question }}
确定
收集问题
{{ item.question }}
确定
您已通过HCP身份认证和信息审核
(
5
s)

一文概括ASCO GI口头报告研究!不容错过的重磅成果,建议收藏转发

2025-12-31作者:论坛报晶资讯
原创

2.35.png

2026年美国临床肿瘤学会胃肠道肿瘤研讨会(ASCO GI)将于2026年1月8~10日在美国旧金山召开,中国医学论坛报特别策划“2026 ASCO GI中国医学论坛报学术联播”专题活动,与您一同精研学术热点,领略大会风采。此次会议中重点介绍了来自各个领域的新兴数据,重磅研究总结如下。


口头摘要专场A:食管癌和胃癌


摘要号:282
英文标题:Perioperative PD-1 antibody toripalimab combined with chemotherapy versus chemotherapy alone in locally advanced gastric or gastroesophageal junction cancer: 3-year follow-up of the prospective, randomized, phase 2 NEOSUMMIT-01 trial
中文标题:围术期特瑞普利单抗联合化疗对比单纯化疗治疗局部晚期胃或胃食管交界处癌:前瞻性、随机、Ⅱ期NEOSUMMIT-01研究3年随访结果

讲者:袁庶强(中山大学肿瘤防治中心)


摘要号:283
英文标题:CRITICS-II: A multicenter randomized phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
中文标题:CRITICS-II研究:可切除胃癌中新辅助化疗序贯手术、新辅助化疗序贯放化疗后手术与新辅助放化疗序贯手术的多中心随机Ⅱ期试验

讲者:Marcel Verheij

摘要号:LBA284
英文标题:Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2+ locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.
中文标题:ILUSTRO 研究:佐妥昔单抗联合mFOLFOX6及纳武利尤单抗一线治疗CLDN18.2阳性局部晚期不可切除/转移性胃或胃食管交界处(mG/GEJ)腺癌的Ⅱ期试验

讲者:Kohei Shitara

摘要号:LBA285
英文标题:Zanidatamab (zani) + chemotherapy (chemo) ± tislelizumab (tisle) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): First results from the phase 3 HERIZON-GEA-01 study
中文标题:泽尼达妥单抗联合化疗±替雷利珠单抗一线治疗HER2阳性晚期/转移性胃食管腺癌:Ⅲ期HERIZON-GEA-01研究首次结果

讲者:Elena Elimova

快速口头摘要专场A:食管癌和胃癌


摘要号:286
英文标题:Tislelizumab plus chemoradiotherapy (CRT) versus CRT or chemotherapy (CT) as the neoadjuvant treatment for patients (pts) with locally advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A multicenter, randomized controlled, open-label, phase IIb study (TERRIFIC)
中文标题:TERRIFIC研究:替雷利珠单抗联合放化疗对比放化疗/化疗新辅助治疗局部晚期胃 / 胃食管交界处腺癌的多中心随机对照开放标签Ⅱb期试验

讲者:魏嘉(南京大学医学院附属鼓楼医院)


摘要号:LBA287
英文标题:Liposomal irinotecan, carboplatin or oxaliplatin (LyRICX) with or without nivolumab in the first-line treatment of metastatic or irresectable esophagogastric adenocarcinoma: A randomized phase 2 study
中文标题:脂质体伊立替康、卡铂或奥沙利铂(LyRICX)方案联合/不联合纳武利尤单抗一线治疗转移性/不可切除食管胃腺癌的随机Ⅱ期研究

讲者:Denice Kamp


摘要号:288
英文标题:Associations between ECOG performance status (PS) and patient-reported outcomes (PROs) in patients with gastric or gastroesophageal junction (G/CEJC) adenocarcinoma: Results from the RATIONALE-305 trial
中文标题:胃或胃食管交界处腺癌患者ECOG体能状态(PS)与患者报告结局(PROs)的相关性分析:来自RATIONALE-305试验的结果

讲者:Marcia Roxana Cruz-Correa


摘要号:289
英文标题:Adjuvant oxaliplatin with S-1 (SOX) versus S-1 in patients with stage II-III gastric or gastro-oesophageal junction adenocarcinoma (CAPITAL): A randomised, open-label, phase 3 trial
中文标题:奥沙利铂联合S-1(SOX)方案对比S-1辅助治疗Ⅱ~Ⅲ期胃或胃食管交界处腺癌:随机开放标签Ⅲ期CAPITAL研究

讲者:聂润聪(中山大学肿瘤防治中心)


摘要号:290
英文标题:Effect of exercise and nutritional prehabilitation on preoperative lean body mass in elderly gastric cancer patients: Results of a randomized controlled trial
中文标题:运动联合营养预康复对老年胃癌患者术前瘦体重的影响:一项随机对照试验结果

讲者:Kazuyoshi Yamamoto


摘要号:291
英文标题:SOX (tegafur plus oxaliplatin) plus anti-PD-1 antibody with or without CAR-like T cell immunotherapy in the treatment of patients with previously untreated metastatic gastric cancer/gastroesophageal junction adenocarcinoma: A multicenter, open-label, randomized, controlled, phase II trial
中文标题:tegafur联合奥沙利铂(SOX)方案联合抗PD-1单抗±CAR-like T细胞免疫治疗初治转移性胃癌/胃食管交界处腺癌的多中心开放标签随机对照Ⅱ期试验

讲者:Qin Liu(南京大学医学院附属鼓楼医院)


口头摘要专场B:胰腺、小肠和肝胆肿瘤


摘要号:476
英文标题:Efficacy and safety of lirafugratinib in FGFRi-naive cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2 f/r)
中文标题:Lirafugratinib治疗FGFR抑制剂初治伴FGFR2融合/重排的胆管癌患者中的疗效和安全性

讲者:Antoine Hollebecque

摘要号:654
英文标题:Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC)
中文标题:新型口服KRAS G12D抑制剂INCB161734单药或联合化疗治疗晚期/转移性胰腺导管腺癌的I期研究初步结果

讲者:Zev A. Wainberg

摘要号:477
英文标题:Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study
中文标题:帕博利珠单抗辅助治疗手术切除/局部消融后达到影像学完全缓解的肝细胞癌患者:III期KEYNOTE-937研究

讲者:Stephen Lam Chan

摘要号:478
英文标题:IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma
中文标题:IKF-035/ABC-HCC研究:阿替利珠单抗联合贝伐珠单抗对比经动脉化疗栓塞(TACE)治疗中期肝细胞癌的IIIb期、随机、多中心、开放标签试验

讲者:Peter Robert Galle


快速口头摘要专场B:胰腺、小肠和肝胆肿瘤


摘要号:653
英文标题:Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
中文标题:Elraglusib联合吉西他滨/白蛋白结合型紫杉醇(GnP)对比GnP治疗初治转移性胰腺导管腺癌的随机II期研究(1801 Part 3B)结果

讲者:Devalingam Mahalingam


摘要号:655
英文标题:Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG)
中文标题:派安普利单抗(PD-1抑制剂)+安罗替尼(抗血管生成靶向药)+白蛋白结合型紫杉醇+吉西他滨一线治疗转移性胰腺癌的多中心、随机对照试验(RCT-PAAG)

讲者:Juan Du(南京大学医学院附属鼓楼医院)


摘要号:LBA479
英文标题:Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW
中文标题:纳武利尤单抗联合伊匹木单抗对比仑伐替尼/索拉非尼一线治疗不可切除肝细胞癌:CheckMate 9DW研究4年随访结果

讲者:Peter Robert Galle


摘要号:724
英文标题:Phase II study of durvalumab plus olaparib in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
中文标题:度伐利尤单抗联合olaparib治疗伴有DNA损伤修复基因改变的转移性胰腺癌患者的II期研究

度伐利尤单抗联合奥拉帕利治疗伴 DNA 损伤修复基因变异转移性胰腺癌患者的 Ⅱ 期试验

讲者:Teresa Macarulla

摘要号:728
英文标题:ALTOPANC: Local ablative therapies in oligometastatic pancreatic adenocarcinoma—A bi-national French-Belgian retrospective study.
中文标题:ALTOPANC研究:寡转移性胰腺腺癌的局部消融治疗——法国-比利时两国回顾性研究

讲者:Anthony Turpin


口头摘要专场C:结直肠癌和肛门癌


摘要号:13
英文标题:BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC)
中文标题:BREAKWATER研究:康奈非尼+西妥昔单抗(EC)+FOLFIRI一线治疗BRAF V600E突变转移性结直肠癌的主要分析

讲者:Scott Kopetz

摘要号:14
英文标题:Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)— NRG-GI004/SWOG-S1610
中文标题:dMMR转移性结直肠癌免疫治疗(COMMIT)研究:阿替利珠单抗单药对比mFOLFOX6+贝伐珠单抗+阿替利珠单抗一线治疗dMMR/MSI-H转移性结直肠癌患者的随机III期研究——NRG-GI004/SWOG-S1610

讲者:Caio Max Sao Pedro Rocha Lima


摘要号:15
英文标题:Diffusion-weighted magnetic resonance imaging versus surgical staging in patients with colorectal peritoneal metastases: The multicenter, international, randomized controlled DISCO trial
中文标题:弥散加权磁共振成像对比手术分期评估结直肠癌腹膜转移患者:多中心、国际、随机对照DISCO试验

讲者:Lizzel van der Snee

摘要号:16
英文标题:Longitudinal study on the influence of physical activity in managing cancer-related fatigue in patients with colorectal cancer
中文标题:身体活动对结直肠癌患者癌因性疲乏管理影响的纵向研究

讲者:Louisa Liu, MD


快速口头摘要专场C:结直肠癌和肛门癌


摘要号:17
英文标题:FOxTROT: Predictive effects of ERBB2 and ERBB3 on neoadjuvant panitumumab benefit in RAS/BRAF wild-type (-wt) locally advanced colon cancer (LACC)
中文标题:FOxTROT研究:ERBB2和ERBB3对RAS/BRAF野生型局部晚期结肠癌新辅助帕尼单抗治疗获益的预测价值

讲者:Jordan Wesley Appleyard

摘要号:18
英文标题:GLP-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: Evidence from a real-world head-to-head comparison.
中文标题:GLP-1受体激动剂对比阿司匹林用于结直肠癌一级预防:真实世界头对头比较的证据

讲者:Colton Jones

摘要号:19
英文标题:Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, <50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC): Insights from real-world data
中文标题:早发性(<50岁)与晚发性(≥50岁)dMMR/MSI-H结直肠癌的分子、临床病理和预后方面差异解析:基于真实世界数据的研究

讲者:Michela Bartolini

摘要号:20
英文标题:Liver transplantation for unresectable colorectal liver metastases: Pooled real-world data from all Belgian liver transplant centers
中文标题:肝移植治疗不可切除结直肠癌肝转移:比利时所有肝移植中心的真实世界汇总数据

讲者:Gertjan Rasschaert

摘要号:1
英文标题:Early outcomes of the PLATO ACT5 randomised trial: Personalizing anal cancer radiotherapy dose.
中文标题:PLATO ACT5研究:肛门癌放疗剂量个体化随机试验早期结果

讲者:Maria A Hawkins


编译自官网

200 评论

查看更多